$7.5 million grant awarded for glaucoma research

The German state of Saxony has granted a $7.5 million grant to Mannin, a technology partner of Q BioMed Inc., to develop novel pharmaceuticals and biologic treatments for glaucoma, according to a press release.

Mannin and Q BioMed are working together to accelerate the development of glaucoma therapies, leveraging two modes of action to reduce intraocular pressure, different routes of administration and different dosing regimens, the release said.

"We are thrilled that we will be able to speed the development of these promising therapeutics and bring new innovation to glaucoma patients as soon as possible,” Q BioMed CEO Denis Corin said. “Our partnership with Mannin and now, the government of Saxony is important to the advancement of this unique drug platform and we look forward to supporting the build-out of the Mannin European headquarters in Leipzig."

Included in the companies’ work is preclinical development of a small molecule pharmaceutical eye drop, as well as a novel recombinant protein injectable biologic.

"We are very encouraged by the confidence and enthusiasm the government of Saxony has shown in our research, and we are committed to making accelerated progress through their investment,” Mannin president and CEO George Nikopoulos said.

The German state of Saxony has granted a $7.5 million grant to Mannin, a technology partner of Q BioMed Inc., to develop novel pharmaceuticals and biologic treatments for glaucoma, according to a press release.

Mannin and Q BioMed are working together to accelerate the development of glaucoma therapies, leveraging two modes of action to reduce intraocular pressure, different routes of administration and different dosing regimens, the release said.

"We are thrilled that we will be able to speed the development of these promising therapeutics and bring new innovation to glaucoma patients as soon as possible,” Q BioMed CEO Denis Corin said. “Our partnership with Mannin and now, the government of Saxony is important to the advancement of this unique drug platform and we look forward to supporting the build-out of the Mannin European headquarters in Leipzig."

Included in the companies’ work is preclinical development of a small molecule pharmaceutical eye drop, as well as a novel recombinant protein injectable biologic.

"We are very encouraged by the confidence and enthusiasm the government of Saxony has shown in our research, and we are committed to making accelerated progress through their investment,” Mannin president and CEO George Nikopoulos said.